Inhibrx Biosciences (NASDAQ:INBX) vs. Voyager Therapeutics (NASDAQ:VYGR) Financial Comparison

Inhibrx Biosciences (NASDAQ:INBX) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Earnings & Valuation

This table compares Inhibrx Biosciences and Voyager Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx Biosciences	$1.30 million	993.60	-$140.05 million	($8.88)	-9.88
Voyager Therapeutics	$40.37 million	2.62	-$119.72 million	($1.73)	-0.98

Voyager Therapeutics has higher revenue and earnings than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

82.5% of Inhibrx Biosciences shares are owned by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are owned by institutional investors. 18.3% of Inhibrx Biosciences shares are owned by insiders. Comparatively, 12.7% of Voyager Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Inhibrx Biosciences and Voyager Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx Biosciences	1	2	2	1	2.50
Voyager Therapeutics	1	0	1	1	2.67

Inhibrx Biosciences presently has a consensus target price of $197.50, suggesting a potential upside of 125.07%. Voyager Therapeutics has a consensus target price of $25.00, suggesting a potential upside of 1,370.59%. Given Voyager Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Voyager Therapeutics is more favorable than Inhibrx Biosciences.

Risk and Volatility

Inhibrx Biosciences has a beta of 4.03, suggesting that its stock price is 303% more volatile than the S&P 500. Comparatively, Voyager Therapeutics has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500.

Profitability

This table compares Inhibrx Biosciences and Voyager Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Inhibrx Biosciences	N/A	-563.90%	-83.48%
Voyager Therapeutics	-416.32%	-63.42%	-49.40%

Summary

Voyager Therapeutics beats Inhibrx Biosciences on 7 of the 13 factors compared between the two stocks.

About Inhibrx Biosciences

Inhibrx Biosciences, Inc. is a U.S.-based biopharmaceutical company focused on developing biologic medicines for cancer and other serious diseases. Its research uses protein engineering to create investigational therapies designed to engage specific targets in the body. The company’s oncology pipeline has included INBRX-109, an antibody designed to activate the DR5 receptor and studied for chondrosarcoma, and INBRX-106, an investigational OX40-targeting antibody. These candidates are experimental and are not approved medicines.

About Voyager Therapeutics

Voyager Therapeutics is a biotechnology company developing genetic medicines for neurological diseases. Its work includes adeno-associated virus (AAV) gene therapies designed to deliver therapeutic genes to the nervous system. The company’s TRACER platform is used to discover and engineer AAV capsids, including candidates intended to cross the blood-brain barrier. Voyager has researched treatments for neurodegenerative and other neurological disorders and has partnered with pharmaceutical companies to advance gene therapy programs.